Mereo Biopharma Group PLC MREO
We take great care to ensure that the data presented and summarized in this overview for Mereo Biopharma Group plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MREO
View all-
Janus Henderson Group PLC London, X022.7MShares$65.2 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$43.9 Million0.99% of portfolio
-
Mangrove Partners New York, NY8.64MShares$24.8 Million3.05% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.82MShares$22.4 Million1.11% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$19.3 Million0.38% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.68MShares$19.2 Million0.9% of portfolio
-
Alkeon Capital Management LLC New York, NY4.7MShares$13.5 Million0.02% of portfolio
-
683 Capital Management, LLC New York, NY4.64MShares$13.3 Million0.84% of portfolio
-
Clearline Capital LP New York, NY3.22MShares$9.24 Million0.47% of portfolio
-
Tejara Capital LTD London, X02.52MShares$7.24 Million2.19% of portfolio
Latest Institutional Activity in MREO
Top Purchases
Top Sells
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Insider Transactions at MREO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
60,046
-6.91%
|
$240,184
$4.22 P/Share
|
|
Sep 13
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
100,312
-36.64%
|
$401,248
$4.22 P/Share
|
|
Sep 13
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,158
-17.67%
|
$76,632
$4.22 P/Share
|
|
Sep 13
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
20,946
-8.73%
|
$83,784
$4.22 P/Share
|
|
Sep 13
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,937
-12.21%
|
$43,748
$4.22 P/Share
|
|
Sep 12
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,611
-3.19%
|
$114,444
$4.47 P/Share
|
|
Sep 12
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
47,798
-12.45%
|
$191,192
$4.47 P/Share
|
|
Sep 12
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,128
-7.76%
|
$36,512
$4.47 P/Share
|
|
Sep 12
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
9,980
-3.99%
|
$39,920
$4.47 P/Share
|
|
Sep 12
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,212
-5.5%
|
$20,848
$4.47 P/Share
|
|
Sep 11
2024
|
Charles Sermon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
65,600
+20.79%
|
-
|
|
Sep 11
2024
|
Christine Ann Fox Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+33.79%
|
-
|
|
Sep 11
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
208,333
+31.41%
|
$0
$0.8 P/Share
|
|
Sep 11
2024
|
Denise Scots Knight Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
188,060
+17.32%
|
-
|
|
Sep 11
2024
|
John A. Lewicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,000
+32.68%
|
-
|
|
Aug 22
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Direct |
105,244
-100.0%
|
$420,976
$4.43 P/Share
|
|
Aug 22
2024
|
Deepika Pakianathan |
BUY
Exercise of conversion of derivative security
|
Direct |
105,244
+33.73%
|
$210,488
$2.28 P/Share
|
|
Jun 26
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
22,968
-39.93%
|
$68,904
$3.39 P/Share
|
|
Jun 26
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
92,273
-11.51%
|
$276,819
$3.39 P/Share
|
|
Jun 26
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,439
-33.83%
|
$88,317
$3.39 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 673K shares |
|---|
| Open market or private sale | 417K shares |
|---|